Rao M R, Padmanaban G
Biochem J. 1973 Aug;134(4):859-68. doi: 10.1042/bj1340859.
Successive administrations of allylisopropylacetamide, a potent porphyrinogenic drug, increase liver weight, microsomal protein and phospholipid contents. There is an increase in the rate of microsomal protein synthesis in vivo and in vitro. The drug decreases microsomal ribonuclease activity and increases NADPH-cytochrome c reductase activity. Phenobarbital, which has been reported to exhibit all these changes mentioned, is a weaker inducer of delta-aminolaevulinate synthetase and increases the rate of haem synthesis only after a considerable time-lag in fed female rats, when compared with the effects observed with allylisopropylacetamide. Again, phenobarbital does not share the property of allylisopropylacetamide in causing an initial decrease in cytochrome P-450 content. Haematin does not counteract most of the biochemical effects caused by allylisopropylacetamide, although it is quite effective in the case of phenobarbital. Haematin does not inhibit the uptake of [2-(14)C]allylisopropylacetamide by any of the liver subcellular fractions.
连续给予烯丙基异丙基乙酰胺(一种强效的致卟啉药物)会增加肝脏重量、微粒体蛋白和磷脂含量。体内和体外微粒体蛋白合成速率均会增加。该药物会降低微粒体核糖核酸酶活性,并增加NADPH-细胞色素c还原酶活性。据报道,苯巴比妥也会出现上述所有这些变化,但与烯丙基异丙基乙酰胺相比,它对δ-氨基-γ-酮戊酸合成酶的诱导作用较弱,并且在喂食的雌性大鼠中,仅在相当长的时间延迟后才会增加血红素合成速率。此外,苯巴比妥不具备烯丙基异丙基乙酰胺那种使细胞色素P-450含量最初降低的特性。血红素不能抵消烯丙基异丙基乙酰胺引起的大多数生化效应,尽管它对苯巴比妥的情况相当有效。血红素不会抑制任何肝脏亚细胞组分对[2-(14)C]烯丙基异丙基乙酰胺的摄取。